西妥昔单抗联合化疗治疗转移性结直肠癌的临床观察  

The Clinical Observation of Cetuximab in Combination with Chemotherapy in Metastatic Colorectal Cancer Patients

作　　者：金璿[1] 白羽[1] 于晶琳[1] 王晓云[1] 徐玲[1] 赵玉亮[1] 

机构地区：[1]北京大学第一医院肿瘤化疗科,北京100034

出　　处：《肿瘤基础与临床》2008年第4期286-288,共3页journal of basic and clinical oncology

摘　　要：目的观察西妥昔单抗联合含伊立替康或奥沙利铂方案治疗转移性结直肠癌的近期疗效、毒副反应。方法8例经病理组织学确诊的转移性结直肠癌入组,均联合FOLFIRI方案或FOLFOX方案治疗,西妥昔单抗首次给予负荷剂量400 mg/m2,而后每周维持量为250 mg/m2。结果全组有7例可评价疗效,PR 3例,SD 4例,有效率42.9%,疾病控制率100%,中位TTP 5.8个月。主要毒副反应为痤疮样皮疹和腹泻。结论西妥昔单抗联合含伊立替康或奥沙利铂方案治疗转移性结直肠癌安全有效。Objective We explored the efficacy and toxicity of cetuximab plus chemotherapy contained irinotecan or oxaliplatin in the treatment of metastatic colorectal cancer. Methods 8 patients with metastatic colorectal cancer with histologically confirmed ,diagnosis were treated with cetuximah in combination with FOLFIRI regimen or FOLFOX regimen. Cetuximah was given at an initial dose of 400 mg/m^2 , followed by weekly infusions of 250 mg/m^2. Results The effect could he observed in 7 patients. 3 patients PR, 4 patients SD, the rate of response was 42.9% and the disease control rate was 100%. The median time of tumor progression was 5.8 months. The major toxicities were acne-like rash and diarrhea. Conclusion Cetuximah in combination with the chemotherapy contained irinotecan or oxaliplatin has clinically activity in patients with metastatic colorectal cancer. The toxicities were tolerable.

关 键 词：转移性结直肠癌 西妥昔单抗 伊立替康 奥沙利铂 

分 类 号：R730.58[医药卫生—肿瘤] R735.35[医药卫生—临床医学]